AUDRITO, VALENTINA
 Distribuzione geografica
Continente #
EU - Europa 749
AS - Asia 665
NA - Nord America 342
SA - Sud America 2
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.761
Nazione #
US - Stati Uniti d'America 336
SG - Singapore 307
HK - Hong Kong 276
IT - Italia 245
RU - Federazione Russa 149
IE - Irlanda 94
DE - Germania 93
ID - Indonesia 47
SE - Svezia 26
GB - Regno Unito 25
CN - Cina 23
UA - Ucraina 23
FI - Finlandia 22
CZ - Repubblica Ceca 16
CH - Svizzera 9
NL - Olanda 9
AT - Austria 7
ES - Italia 7
LT - Lituania 6
BE - Belgio 5
CA - Canada 5
KR - Corea 5
FR - Francia 3
GR - Grecia 3
PK - Pakistan 3
RO - Romania 3
HR - Croazia 2
IN - India 2
AR - Argentina 1
AU - Australia 1
BR - Brasile 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
IL - Israele 1
IQ - Iraq 1
MX - Messico 1
PT - Portogallo 1
Totale 1.761
Città #
Hong Kong 276
Singapore 121
Dublin 94
Milan 46
Jakarta 41
Turin 31
Jacksonville 30
Novara 28
Boardman 26
Vercelli 21
Munich 20
Moscow 18
Brno 16
Chandler 16
Dearborn 13
Falkenstein 12
Helsinki 11
Nuremberg 11
Frankfurt am Main 10
Ashburn 8
London 7
Bologna 6
Lawrence 6
Manchester 6
Princeton 6
Rome 6
Vienna 6
Wilmington 6
Amsterdam 5
Beijing 5
Zurich 5
Como 4
New York 4
San Mateo 4
Valencia 4
Andover 3
Athens 3
Bari 3
Beauharnois 3
Bern 3
Brussels 3
Irvington 3
Kunming 3
Mülheim 3
Palo Alto 3
Piemonte 3
Rawalpindi 3
Santa Clara 3
Truccazzano 3
Alaquàs 2
Bulgarograsso 2
Casatenovo 2
Catania 2
Chongqing 2
Croydon 2
Genoa 2
Kensington 2
Las Vegas 2
Mobile 2
Modena 2
Nichelino 2
Oleggio 2
Philadelphia 2
Pollenza 2
Queens 2
Rapallo 2
Rockville 2
Sona 2
The Bronx 2
Tomball 2
Toronto 2
Ulsan 2
Zagreb 2
Ann Arbor 1
Balasore 1
Bethesda 1
Brisbane 1
Buffalo 1
Cairo 1
Caravaggio 1
Chengdu 1
Chicago 1
Cuorgnè 1
Edinburgh 1
Fairfield 1
Floreşti 1
Ghent 1
Gravellona Toce 1
Hefei 1
Horia 1
Houston 1
Kirkuk 1
Leuven 1
Los Angeles 1
Madrid 1
Manassas 1
Mexico City 1
Mishmarot 1
Monza 1
Nanjing 1
Totale 1.046
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 76
Bi-directional crosstalk between NAD/NAMPT and IFN-γ/PD-L1axes in melanoma 72
The Extracellular NADome Modulates Immune Responses 70
A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment 67
HLA-G IS A COMPONENT OF THE CLL ESCAPE REPERTOIRE TO GENERATE IMMUNE SUPPRESSION: IMPACT OF HLA-G 14 BP (RS66554220) POLYMORPHISM 56
NAMPT in drug-resistant melanoma: linking NAMPT-dependent metabolic reprogramming and immune regulation 53
A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment 51
Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network 50
Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed and abundantly released from malignant pleural mesothelioma cells becoming a potential biomarker. 48
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 47
Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma 45
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 45
P13-17: Effect of Ether Perfluoro Carboxyl Acid (PFAS) on Innate Immunity in Earthworms 37
NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets 35
NAMPT inhibition impairs mTOR-dependent regulation of translation in melanomaNAMPT inhibition impairs mTOR-dependent regulation of translation in melanoma. 34
Procedimento immunologico e kit per la diagnosi in vitro di patologie tumorali e/o infiammatorie 30
Protective Role of the M-Sec-Tunneling Nanotube System in Podocytes 30
Investigating the presence of eNAMPT/visfatin in human skimmed milk and milk fat globule membrane before and after Holder pasteurization. 29
The Role of the Toll-like Receptor 2 and the cGAS-STING Pathways in Breast Cancer: Friends or Foes? 28
The hidden life of NAD+-consuming ectoenzymes in the endocrine system 28
Immunological method and kit for in vitro diagnosis of tumor and/or inflammatory diseases 27
Impact of Holder pasteurization on protein and eNAMPT/Visfatin content in human breast milk 27
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 24
Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties 24
null 23
Abstract 2630: Nicotinamide activates the p53/miR-34a/SIRT1 tumor suppressor network leading to apoptosis of chronic lymphocytic leukemia cells 23
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies 23
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 23
Extracellular nicotinate phosphoribosyltransferasebinds Toll like receptor 4 and mediatesinflammation 23
BRAF-mediated NAMPT overexpression induces a melanoma cell dedifferentiation program leading to metabolic reprogramming and intrinsic resistant to BRAF inhibitors 22
CD38 in chronic lymphocytic leukemia: from bench to bedside? 22
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia 22
DIFFERENT AQUAPORIN-4 EXPRESSION IN GLIOBLASTOMA MULTIFORME PATIENTS WITH AND WITHOUT SEIZURES 21
Abstract 2302: The extracellular form of NAMPT contributes to creating a proinflammatory environment in chronic lymphocytic leukemia 20
Abstract 5170: Metabolism and cancer: The CD38-NAMPT connection in chronic lymphocytic leukemia 20
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma 19
Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism 19
Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT) 19
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer 19
The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer 18
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation 18
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle 17
The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle 16
Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle 16
TBC1 domain-containing proteins are frequently involved in triple-negative breast cancers in connection with the induction of a glycolytic phenotype 15
Targeting mitochondria by ss-31 ameliorates the whole body energy status in cancer-and chemotherapy-induced cachexia 15
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma 15
Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications 15
NAMPT: A critical driver and therapeutic target for cancer 15
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma 15
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition 15
miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression 14
RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition 14
The heme exporter FLVCR1a modulates the tricarboxylic acid cycle: a new target in colorectal cancer 14
Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle 14
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 14
Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death 14
Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia 14
Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and Toll-like receptor 4 14
Loss of the heme exporter FLVCR1a impairs mitochondrial functionality: a new approach against colorectal cancer 13
NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model 13
The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting 13
Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options 13
Targeting the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Novel Therapeutic Opportunities 12
Nampt over-expression recapitulates the braf inhibitor resistant phenotype plasticity in melanoma 12
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation 12
Pancreatic cancer immune evasion mechanisms: the immunosuppressive role of P2RX1-negative neutrophils 12
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 11
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 11
SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy 11
Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma 11
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia 11
NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer 10
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics 10
Subcellular characterization of NAD+ biosynthesis in metastatic melanoma by using organelle-specific biosensors 9
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 9
Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting 7
Totale 1.853
Categoria #
all - tutte 15.562
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.562


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 3 6 0
2020/202131 5 0 5 0 5 0 5 1 5 0 5 0
2021/202228 0 0 4 1 1 0 2 2 1 5 4 8
2022/2023197 6 5 7 2 3 17 3 12 119 6 9 8
2023/2024389 13 26 32 18 62 4 86 33 6 5 22 82
2024/20251.125 46 5 119 34 92 54 177 91 456 51 0 0
Totale 1.853